Background-This study evaluated the risk of upper gastrointestinal bleeding (UGIB) associated with use of low-dose acetylsalicylic acid (ASA) alone and in combination with other gastrotoxic medications. 
A ntiplatelet therapy with low-dose acetylsalicylic acid (ASA) (75 to 325 mg/d) and clopidogrel, alone or in combination, is now standard for the secondary prevention of cardiovascular events. 1 These drugs have been shown to reduce the risk of cardiovascular events when used as monotherapy 2 and in combination. 3 Guidelines recommend the use of combination antiplatelet therapy for up to 1 year after myocardial infarction or acute coronary syndromes. 4 However, clinical trials have shown that both low-dose ASA and clopidogrel are associated with an increased risk of upper gastrointestinal bleeding (UGIB), and there is evidence to suggest that this risk is increased further with the combination of the 2 therapies. 2, 3 
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Other medications commonly coadministered with antiplatelet therapy such as nonsteroidal antiinflammatory drugs (NSAIDs), oral anticoagulants, and corticosteroids are also known to increase the risk of UGIB. [5] [6] [7] [8] [9] Although concomitant use of these medications and antiplatelet therapy might increase the risk of UGIB further and thus change the risk-to-benefit ratio, very few studies have actually quantified the risk of UGIB associated with specific combination therapies in the general population.
The aims of this study were to examine the risk of UGIB among users of low-dose ASA and clopidogrel (either alone or in combination) and to assess the effects of concomitant administration of other gastrotoxic medications on this risk of UGIB in the general population.
primary care database. Anonymized data on Ͼ3 million patients are systematically recorded by participating primary care practitioners (PCPs) as part of their routine patient care and sent to THIN for use in research projects.
THIN contains patient information such as demographic factors, consultation rates, referrals, hospitalizations, laboratory test results, and prescriptions ordered by PCPs, including the doses and duration of treatment. Diagnoses and test procedures are recorded with Read Codes. 10 Prescriptions written by PCPs are generated and recorded automatically in the database with the use of a coded drug dictionary (Multilex). 11 Previous studies have provided evidence to support the validity of THIN in pharmacoepidemiological research, particularly when UGIB is the outcome of interest. 12, 13 The source population for this study comprised all individuals recorded in THIN who were 40 to 84 years of age from January 1, 2000, to December 31, 2007, and were enrolled permanently with a PCP. Individuals were included in the source population only if they had been enrolled with their PCP for at least 2 years and had a computerized prescription history of at least 1 year. Patients with a recorded diagnosis of cancer, esophageal varices, Mallory-Weiss disease, alcohol abuse, liver disease, or coagulopathy before the start date were excluded from the source population. Individuals Ն65 years of age at the start date who had a follow-up of Ͼ1 year but no recorded data during the follow-up period were excluded as a proxy for incomplete data recording.
All members of the source population were followed up from the start date until the earliest of the following end points: recorded diagnosis of UGIB (case detection), recorded diagnosis of an exclusion factor, reaching 85 years of age, death, or the end of the study period. The computerized patient profiles of all potential cases were reviewed manually after incorporating free-text comments. Individuals were considered to be UGIB cases if they had no exclusion criteria in the 2 months after the recorded UGIB, if they had not been discharged from the hospital in the previous month, and if their bleed was located in the stomach or duodenum. Patients with bleeding in the esophagus or lower gastrointestinal tract were excluded.
The present study is an extension of an earlier study that demonstrated the validity of the procedure used for ascertaining UGIB events. 7 A positive predictive value of Ͼ95% was estimated for the UGIB definition compared with PCPs' records in a random sample. 7, 12 Therefore, no further validation was performed as part of the present study.
After the manual review of computerized records, the final number of confirmed cases of UGIB was 2049. A control group of 20 000 individuals, frequency matched by age, sex, and calendar year to the cases, was randomly sampled from the same source population.
Analysis
Computerized prescription records were used to assess the use of low-dose ASA (75 to 300 mg/d), clopidogrel, oral anticoagulants, NSAIDs (selective inhibitors of cyclooxygenase-2 [coxibs] and traditional NSAIDs), oral corticosteroids, selective serotonin reuptake inhibitors and statins before the index date (for cases, this was the date of the UGIB diagnosis; for controls, it was a random date during follow-up). Drug exposure was classified into 2 categories based on the expected pharmacological effects: current use, defined as use lasting until the index date or ending in the 30 days before the index date, and past use, defined as use ending 31 to 365 days before the index date. However, in a previous study, 14 we found that the risk of UGIB among NSAID users starts to decrease quite markedly around 7 days after treatment cessation, reflecting the reversible nature of the inhibition of cyclooxygenase by NSAIDs. Therefore, for NSAID use, current use was defined as lasting until the index date or ending in the 7 days before the index date, recent use was defined as ending 8 to 90 days before the index date, and past use was defined as ending 91 to 365 days before the index date. For all studied medications, the reference group (nonuse) was defined as no exposure to the drug in the year before the index date. It should be noted, however, that a minority of the individuals in the nonuse group may have been taking over-the-counter low-dose ASA or NSAIDs. To eliminate any continued effects from the previous medication after recent switching from low-dose ASA to clopidogrel or vice versa, monotherapy with ASA or clopidogrel was defined as current use of the drug in question with no use of the other antiplatelet drug in the previous year. The risk of UGIB in new users was evaluated in subanalyses to assess any potential selection bias when considering long-term users. NSAIDs and oral corticosteroids were stratified by daily dose (see the online-only Data Supplement for more information).
Nested case-control analysis was performed to estimate the age-, sex-, and calendar year-adjusted relative risk (RR) of UGIB associated with the use of low-dose ASA and clopidogrel and the risk associated with other gastrotoxic medications. Fully adjusted RRs and 95% confidence intervals (CIs) were calculated with unconditional logistic regression. These estimates were further adjusted by number of PCP visits and hospitalizations in the year before the index date, history of peptic ulcer disease, smoking status, alcohol consumption, and use of oral corticosteroids, selective serotonin reuptake inhibitors, oral anticoagulants, NSAIDs, ASA, nitrates, histamine-2 receptor antagonists, and proton pump inhibitors in the year before the index date.
Results

Risk Factors for UGIB
Risk factors for UGIB are shown in Table 1 . The risk of UGIB was significantly higher in individuals with a history of upper gastrointestinal disease than in those without. There was no significant association between a history of cardiovascular disease and the risk of UGIB in the fully adjusted analysis. The associations between these factors and the risk of UGIB were similar when the analysis was restricted to users of antiplatelet therapy (data not shown).
Antiplatelet Therapy and UGIB
Of the 2049 confirmed UGIB cases, 631 (30.8%) were taking low-dose ASA at the time of the event, 68 (3.3%) were taking clopidogrel, and 32 (1.6%) were taking low-dose ASA and clopidogrel (Table 2) . Compared with nonuse of either ASA or clopidogrel, low-dose ASA monotherapy was associated with an increased risk of UGIB (RR, 1.79; 95% CI, 1.57 to 2.03; Figure 1 and Table 2 ). This increased risk of UGIB was similar in patients who had received ASA monotherapy for Ͼ365 days and for Յ365 days ( Table 2 ). The risk of UGIB was also similar across all of the daily doses of ASA studied. The RR of UGIB among users of clopidogrel monotherapy, compared with those not taking either ASA or clopidogrel, was 1.48 (95% CI, 0.96 to 2.27; Figure 1 and Table 2 ). This increase in risk was similar regardless of the duration of therapy. More than 95% of patients taking clopidogrel were receiving 75 mg/d; therefore, an analysis of any doseresponse relationship with UGIB was not possible.
The RR of UGIB in patients receiving low-dose ASA and clopidogrel combination therapy was 3.71 (95% CI, 2.38 to 5.76) compared with those receiving neither antiplatelet therapy ( Figure 1 and Table 2 ) and 2.08 (95% CI, 1.34 to 3.21) compared with those receiving low-dose ASA alone (Figure 2 ).
Other Medications and UGIB
Among the 2049 patients with confirmed UGIB, 113 (5.5%) were receiving oral anticoagulants at the time of the event, 370 (18.1%) were receiving NSAIDs, 87 (4.2%) were taking oral corticosteroids, 519 (25.3%) were taking statins, and 123 (6.0%) were taking selective serotonin reuptake inhibitors ( Table 3) .
The risk of UGIB was increased in current users of oral anticoagulants, NSAIDs, or oral corticosteroids compared with those not taking these medications (Table 3 ). The increase in the risk of UGIB associated with corticosteroids was significant only in those using high-dose oral corticosteroids, not in those taking low-/medium-dose oral corticosteroids. However, the increased risk of UGIB associated with NSAID use was observed with both high and low doses of NSAIDs. There was a small increase in the risk of UGIB associated with current selective serotonin reuptake inhibitor use, but it did not reach significance. There was also no significant association between statin use and the risk of UGIB.
Concomitant Medication Increases the Risk of UGIB
Compared with nonuse of either low-dose ASA or oral anticoagulants, the RR of UGIB was 3.62 (95% CI, 2.09 to 6.29) for individuals receiving low-dose ASA and oral anticoagulants (Table 4 and Figure 1 ). Compared with lowdose ASA monotherapy, concomitant use of low-dose ASA and oral anticoagulants was associated with a significant increase in the risk of UGIB (Figure 2) .
Similarly, compared with nonuse of either low-dose ASA or NSAIDs, the RR of UGIB was 4.80 (95% CI, 3.53 to 6.55) for concomitant users of a low-/medium-dose NSAID and low-dose ASA and 4.86 (95% CI, 3.44 to 6.84) for concomitant users of a high-dose NSAID and low-dose ASA (Table  4 and Figure 1) . Compared with the use of low-dose ASA alone, the risk of UGIB was significantly higher in individuals taking low-dose ASA and a low-/medium-dose NSAID and in those taking low-dose ASA and a high-dose NSAID (Figure 2) .
When users of NSAIDs were separated into those using traditional NSAIDs and those using coxibs, the risk of UGIB was significantly increased in patients taking traditional NSAIDs but not low-dose ASA and in those taking coxibs but not low-dose ASA compared with individuals taking neither the respective medication nor low-dose ASA (Table 4 and Figure 1 ). The risk of UGIB was increased further in individuals taking traditional NSAIDs and low-dose ASA and in those taking coxibs and low-dose ASA.
Compared with patients not receiving either oral corticosteroids or low-dose ASA, the RR of UGIB was 7.87 (95% CI, 3.73 to 16.63) for concomitant users of high-dose oral corticosteroids and low-dose ASA and 1.80 (95% CI, 1.03 to 3.15) for concomitant users of low-/medium-dose corticosteroids and low-dose ASA (Table 4 ; Figure 1 ). Compared with the use of low-dose ASA alone, the RR of UGIB was significantly higher in patients receiving a combination of high-dose corticosteroids and low-dose ASA but not in individuals taking low-/medium-dose corticosteroids and low-dose ASA (Figure 2 ).
Concomitant treatment with low-dose ASA and statins was not significantly associated with the risk of UGIB compared with low-dose ASA monotherapy (RR, 0.99; 95% CI, 0.81 to 1.21). Likewise, concurrent use of selective serotonin reuptake inhibitors and low-dose ASA did not significantly increase the risk of UGIB compared with low-dose ASA monotherapy (RR, 0.80; 95% CI, 0.54 to 1.20) .
Discussion
In this large-scale study in UK primary care, treatment with low-dose ASA monotherapy or clopidogrel monotherapy was associated with an increase in the risk of UGIB compared with nonuse of either therapy. Low-dose ASA monotherapy and clopidogrel monotherapy increased the risk of UGIB by a similar extent, which suggests that neither therapy is superior to the other in terms of their UGIB risk profile. The risk of UGIB associated with ASA or clopidogrel as monotherapies appeared to be independent of the duration of therapy; dose effects could not be fully evaluated in this study. Combination therapy with low-dose ASA and clopidogrel was associated with a greater increase in the risk of UGIB than either monotherapy; the risk was estimated to be 2.4-to 5.8-fold greater than that associated with nonuse of either therapy.
Clinical trials have shown that combination therapy with clopidogrel and low-dose ASA is associated with an increased risk of UGIB compared with low-dose ASA alone. 2 However, there are limited data on the safety of the combination of these 2 antiplatelet therapies in the general population. One population-based case-control study in Denmark reported that, compared with nonuse of any antiplatelet therapy, combination therapy with clopidogrel and ASA was associated with a significant increase in the risk of UGIB (odds ratio, 7.4; 95% CI, 3.5 to 15.0). 15 The corresponding odds ratio for ASA monotherapy was 1.8 (95% CI, 1.5 to 2.1), whereas the odds ratio for clopidogrel monotherapy was 1.1 (95% CI, 0.6 to 2.1). A more recent study of nationwide registries in Denmark found that, in patients with acute myocardial infarction, ASA and clopidogrel combination therapy was associated with a higher risk of any bleeding event than ASA monotherapy (hazard ratio [HR], 1.47; 95% CI, 1.28 to 1.69). 16 In contrast to the results of the present study, the recent Danish study also found clopidogrel monotherapy to be associated with a higher risk of any bleeding event than ASA monotherapy (hazard ratio, 1.33; 95% CI, 1.11 to 1.59). It is important to note that this study examined all types of bleeding, whereas we focused on UGIB. In addition, their findings may be explained by clopidogrel being prescribed to patients with a higher baseline risk of UGIB. To reduce this potential bias in the present study, our estimates were adjusted for UGIB risk factors. Moreover, we defined monotherapy with clopidogrel as current use of clopidogrel with no record of low-dose ASA use in the previous year to account for the fact that some patients may have switched from low-dose ASA to clopidogrel because of gastrointestinal intolerance. Because these factors were not considered in the Danish study, it is not surprising that they reported a higher risk of bleeding associated with clopidogrel monotherapy compared with low-dose ASA monotherapy than shown in our study. Indeed, when we adjusted only for matching factors, the RR of UGIB was 2.6 for current use of clopidogrel and 2.1 for current use of low-dose ASA.
As the most commonly prescribed medicine for primary or secondary prevention of cardiovascular events, low-dose ASA is frequently coprescribed with other gastrotoxic agents. This study shows that patients receiving low-dose ASA along with other gastrotoxic medications have a significantly greater increase in the risk of UGIB than patients receiving low-dose ASA alone. There was an almost 8-fold increased risk of UGIB associated with concomitant use of low-dose ASA and high-dose corticosteroids compared with nonuse of either drug, which suggests that caution is warranted before prescribing such a combination of treatments. Such an interaction was not observed with concomitant administration of low-dose ASA and low-/medium-dose oral corticosteroids.
There was no significant association (in either direction) between statin use and the risk of UGIB. This was the case in the total study population and in those taking low-dose ASA.
This study provides support for the results of several previous observational studies on this topic, which also found no association between statin use and gastrointestinal bleeding. 17, 18 A retrospective, posthoc analysis of a clinical trial of orbofiban found statin users in the active treatment group to be at a lower risk of some categories of gastrointestinal bleeding than individuals not taking statins (1.0% versus 1.9%; PϽ0.001). 19 However, this trial was not randomized with regard to statin use, and statin use was not associated with a significant reduction in gastrointestinal bleeding in the placebo group. Our results therefore add weight to the suggestion that statins are not protective against UGIB.
Strengths and Limitations
A major strength of this study is its large sample size. In addition, patients recorded within THIN are representative of the entire UK general population. 20 Furthermore, the outcome of this study has been validated: Ͼ95% of UGIB cases from a random sample were confirmed on consultation with the PCPs in a previous study. 7, 12 A limitation of THIN is that it captures only recorded prescription medications. It is likely that some patients were using over-the-counter ASA or NSAIDs and may have been misclassified as nonusers in this study. However, over-thecounter use of low-dose ASA in elderly populations is low in the United Kingdom, 21 and significant underrecording of the use of low-dose ASA is unlikely given that prescriptions are free for patients Ͼ60 years of age. Furthermore, in a previous study, the influence of underrecording of ASA use on odds ratios was investigated and found to be minimal. 22 
Conclusions and Clinical Implications
The present study confirms the increase in the risk of UGIB associated with ASA and clopidogrel monotherapies in the general population. Use of low-dose ASA or clopidogrel is associated with an almost 2-fold increase in the risk of UGIB compared with nonuse. Concomitant use of low-dose ASA with clopidogrel or other gastrotoxic medications is associated with an even greater increase in the risk of UGIB than that conferred by the monotherapies. The incidence of UGIB has been estimated to be between 0.5 and 1 per 1000 person-years in the general population. 23 The RR of 3.7 associated with current use of dual antiplatelet therapy in the present study would therefore translate to an excess risk of UGIB on the order of 1.4 to 2.7 cases among 1000 exposed individuals annually.
Several studies have assessed the risks and benefits of ASA in various settings and have tended to conclude that the cardiovascular benefits of ASA definitely outweigh its gastrointestinal risks when it is used in secondary prevention 24 but not necessarily when it is used in primary prevention, particularly not if individuals are already taking statins. 24, 25 These modeling studies often take into account only the age of patients when assessing the risks and benefits of ASA. However, our results suggest that they should also take into account the other gastrotoxic agents that may be coadministered to these patients.
